The ECHO trial, a randomized clinical trial, was developed to address a long-standing question about the possible association of hormonal contraceptives with increased HIV acquisition risk. This article presents the data from research sites in Eswatini, Kenya, South Africa and Zambia. The results indicate there were no substantial differences in HIV incidence associated with use of three licensed contraceptive methods and supports continued and expanded access to these methods.
HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: A randomised, multicentre, open-label trial
Written By
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium [FHI 360 staff: Tim Mastro, Charlie Morrison, Kavita Nanda, Kathleen Shears, Doug Taylor, Julia Welch]
